Viral Vector Process Development Summit

Topics

• Bridging the gap between USP and DSP, and purification techniques to yield a pure viral vector drug product
• Novel strategies to optimize upstream viral vector processes with improved cell line suspension
• Reducing impurity and maximizing process development robustness for greater process control and quality
• Formulation for a stable viral vector product compare and contrast viral vector process development for cell and gene therapies
• The fast-evolving regulatory landscape to achieve GMP during scale up and scale out